The combination of FGFR inhibitors with agents targeting AKT/mTOR signaling pathway increases the anti-tumor effects induced by FGFR inhibition; this drug combination could represent a new therapeutic strategy for FGFR1-amplified LSQCCs [56]. The gene discussed is AKT1; the disease is neoplasm.